Lidocaine: Effect of Lidocaine in Chronic Cough

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University Hospital of South Manchester NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT01252225
First received: November 29, 2010
Last updated: September 15, 2011
Last verified: September 2011
  Purpose

People cough in order to clear their airways. Most coughs are caused by viruses and settle down by themselves, but some people develop persistent coughing which can be anywhere from 8 weeks to several years. This is called chronic cough. People with chronic cough find the symptom distressing and it can have a major impact on their quality of life. Patients with chronic cough often report a sensation at the back of their throat which makes them feel an urge to cough. There is some evidence that Lidocaine (an anaesthetic used during medical procedures) can suppress a person's cough when given to patients via a nebuliser (a machine that turns liquid into a fine mist).

It is currently unknown whether using a local anaesthetic, such as Lidocaine, in the form of a throat spray would successfully suppress a person's cough. A throat spray would be an easier treatment option in chronic cough patients. Thus, the investigators research aims to compare cough rates, severity and urge to cough scores between Lidocaine throat spray and nebulised Lidocaine.


Condition Intervention Phase
Chronic Cough
Drug: 10 % Lidocaine
Drug: 0.9% saline
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Lidocaine and Its Delivery in Patients With Chronic Cough

Resource links provided by NLM:


Further study details as provided by University Hospital of South Manchester NHS Foundation Trust:

Primary Outcome Measures:
  • Objective cough counts over 10 hours post dose. Change in Urge to cough and Visual Analogue Score (VAS). [ Time Frame: over 24 hours following treatment ] [ Designated as safety issue: No ]
    patients will wear a cough recorder device for a 24 hour period. The recordings will then be analysed to reveal how many times the patient coughed.


Secondary Outcome Measures:
  • Heart rate [ Time Frame: over 2 hours ] [ Designated as safety issue: Yes ]
    to document any change in heart rate after treatment

  • Mouth Numbness [ Time Frame: over 24 hours following treatment ] [ Designated as safety issue: No ]
    Duration of mouth numbness will be subjectively assessed by asking patients about the presence of mouth numbness and its duration after treatment.

  • Electrocardiogram (ECG) [ Time Frame: 15 minutes after treatment ] [ Designated as safety issue: Yes ]
    ECG will be recorded before treatment and 15 minutes after treatment to rule out any arrhythmias


Estimated Enrollment: 30
Study Start Date: February 2011
Study Completion Date: May 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Nebulised Lidocaine followed by Placebo throat spray Drug: 10 % Lidocaine
600 mg Nebulised Lidocaine ( 6 mls of 10 % Lidocaine) one-off dose
Other Names:
  • Lidocaine
  • Lignocaine
Active Comparator: Nebulised Placebo followoed by Lidocaine Throat Spray Drug: 10 % Lidocaine
100 mg Lidocaine ( 1 ml of 10 % Lidocaine) given as one-off throat spray.
Other Names:
  • Lidocaine
  • Lignocaine
Placebo Comparator: Nebulised placebo followed by placebo throat spray Drug: 0.9% saline
6 mls of 0.9% saline nebulised followed by 1 ml of 0.9% saline as throat spray

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female subjects, age 18 years and over.
  • History of cough for more than 8 weeks.
  • Normal chest x ray
  • Chronic idiopathic cough or chronic cough resistant to treatment of specific triggers.

Exclusion Criteria:

  • Smoking status:

    • Current smokers
    • Ex smokers with history of smoking > 20 pack years or those who have given up < 6 months ago.
  • Prohibited medications:

    • Use of medications likely to suppress / affect cough including codeine, morphine, pregabalin, gabapentin, amitriptylline, angiotensin converting enzyme inhibitors (type 1) and baclofen.
    • Use of any anti-arrhythmic medication.
    • Use of cimetidine, beta blockers, or diuretics.
  • Cardiovascular conditions:

    • Sinoatrial disease, bradycardia or all types of heart blocks.
    • History of ischaemic heart disease or heart failure.
    • Clinically significant abnormal electrocardiogram (ECG) at Screening or Baseline.
    • History of cardiac surgery
  • Respiratory conditions:

    o Asthma.

  • Central nervous system / Peripheral nervous system conditions:

    • Epilepsy.
    • Myasthenia gravis.
  • Miscellaneous:

    • History of hepatic or renal dysfunction.
    • Porphyria
    • History of hypersensitivity to Lidocaine or related drugs.
    • Pregnancy or breast feeding.
    • Participation in another trial within the preceding 6 weeks.
    • Trauma or ulceration to oral mucosa.
    • History of chest or upper airway infection within the past 6 weeks.
    • Conditions which may affect cough response such as stroke, diabetes, Parkinson's Disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01252225

Locations
United Kingdom
University Hospital of South Manchester
Manchester, United Kingdom, M23 9LT
Sponsors and Collaborators
University Hospital of South Manchester NHS Foundation Trust
Investigators
Principal Investigator: Ashley Woodcock, MD, FRCP University of Manchester
  More Information

No publications provided

Responsible Party: University Hospital of South Manchester NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT01252225     History of Changes
Other Study ID Numbers: Lidocaine1
Study First Received: November 29, 2010
Last Updated: September 15, 2011
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by University Hospital of South Manchester NHS Foundation Trust:
Chronic Cough
Lidocaine

Additional relevant MeSH terms:
Cough
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Lidocaine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Anti-Arrhythmia Agents
Cardiovascular Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 16, 2014